

FORM PTO1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.	SERIAL NO.
		APPLICANT Edward T. Wei	
		FILED September 11, 2003	GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	Class	Sub Class	Filing Date
	A1	4	0	7	0	4	9	6		1/24/78	Rowsell and Spring		
	A2	5	5	8	2	3	3	0		12/28/94	Iba		
	A3												
	A4												
	A5												
	A6												
	A7												
	A8												
	A9												
	A10												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	Class	Sub Class	Trans? (Yes/No)
	B1												
	B2												
	B3												
	B4												
	B5												

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)

	C1	Code of Federal Regulations, Section 21 Part 349, Ch. 1(4-1-01 Edition). pg. 270 to 275. Ophthalmic Drug Products for Over-the Counter Human Use.
	C2	G. Hecht, Ophthalmic Solutions, Chapt 43, pg. 821-835, in "Remington, the Science and Practice of Pharmacy," Alfonso R. Gennaro, Editor. 20th ed. Baltimore, Md.: Lippincott Williams & Wilkins, 2000.
	C3	H.R. Watson, R. Hems, D.G. Rowsell and D.J. Spring. New Compounds with the Menthol Cooling Effect. Journal of the Society of Cosmetic Chemistry. 29: 185-200, 1978.

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.